Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy
European Journal of Clinical Microbiology & Infectious Diseases1986Vol. 5(5), pp. 513–517
Citations Over Time
R. J. Stockley, Tawfique K. Daneshmend, Maria Bredow, David W. Warnock, Malcolm Richardson, Robert Slade
Related Papers
- → Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug–drug interactions(2011)41 cited
- → Use of physiological based pharmacokinetic modeling for cross-species prediction of pharmacokinetic and tissue distribution profiles of a novel niclosamide prodrug(2023)10 cited
- → Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS‐690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically‐Based Pharmacokinetic Simulations(2012)13 cited
- → Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro(2018)4 cited
- → Inhibition of Triazolam Hydroxylation by Ketoconazole, Itraconazole, Hydroxyitraconazole and Fluconazole In‐vitro(1998)22 cited